logo-loader
AIM:EVG

Evgen Pharma PLC

Receive alerts
Market:
AIM
Price
0.90 GBX
Day Change
2.86%
Market Cap:
£2.47 m
52 weeks high
4.05
52 weeks low
0.81

In brief

Evgen Pharma PLC is a clinical-stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases.

The company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane. 

Evgen Pharma's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the company's new enteric-coated tablet formulation.